Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo Therapeutics reports progress in gene therapies

However, the company is currently not profitable, with a negative P/E ratio of -2.88 over the last twelve months as of Q2 2024. This aligns with ...

Sangamo Therapeutics Reports Strong Q3 2024 Growth - TipRanks

Key financial highlights show a remarkable increase in revenue from $9.4 million to $49.4 million compared to the same period last year, ...

Sangamo Therapeutics Inc, SGMO:DEU summary - FT.com

Latest Sangamo Therapeutics Inc (SGMO:DEU) share ... Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results ...

Investors & Media - Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results ; Income tax expense (benefit).

Sangamo Revenue Drops Due To Collaboration Endings

Sangamo Therapeutics Inc., a genomic medicine company, has reported business highlights and second quarter 2024 financial results. Revenues ...

Sangamo Therapeutics Announces Third Quarter 2024 Conference ...

RICHMOND, Calif. / Nov 04, 2024 / Business Wire / Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo Therapeutics, Inc. , a genomic medicine company, today reported business highlights and third quarter 2024 financial results.

Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo Therapeutics. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results (Businesswire).

Sangamo Biosciences: Promising Financial Position and Strategic ...

Ritu Baral has given her Buy rating due to a combination of factors that highlight Sangamo Biosciences' promising financial and strategic ...

News Releases | Investor Relations | Sangamo Therapeutics, Inc.

Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease · Sangamo Therapeutics Reports Recent ...

Voyager Reports Third Quarter 2024 Financial and Operating Results

... Recent Highlights. Licensed TRACER™ capsid to Novartis in 5th partnered ... Sangamo Therapeutics, Inc. For more information, visit www ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Sangamo Therapeutics. Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results (Businesswire).

Barclays Raises Sangamo Therapeutics (NASDAQ:SGMO) Price ...

Barclays boosted their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an "overweight" rating in a research ...

Voyager Reports Third Quarter 2024 Financial and Operating Results

Third Quarter 2024 and Recent Highlights. Licensed TRACER™ capsid to ... Sangamo Therapeutics, Inc. For more information, visit www ...

Fierce Biotech Layoff Tracker 2024

July 25 - Relay Therapeutics: Precision medicine company Relay has undergone a workforce reduction that will include less than 5% of all employees at the 300- ...

Analyst Upgrades & Downgrades - MarketWatch

Showing last 200 actions. See The Ratings Game for highlights. Date, Symbol, Company, Category, Analyst Firm, Info ...

News Releases | Investor Relations - Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results ... Conference Call and Webcast Scheduled for 4:30 p.m. Eastern ...

Sangamo price target raised to $3 from $1 at Wells Fargo - TipRanks

Wells Fargo raised the firm's price target on Sangamo (SGMO) to $3 from $1 and keeps an Equal Weight rating on the shares.

Revolution Medicines

With our deep pipeline of RAS(ON) inhibitors, we are pioneering a new way of drugging the previously undruggable, with the potential to change the treatment ...

Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript

This call includes forward-looking statements regarding Sangamo's current expectations. These statements include but are not limited to ...